An­oth­er Eylea com­peti­tor pre­pares to en­ter the ring fol­low­ing pos­i­tive PhI­II read­out

Re­gen­eron may soon be star­ing down an­oth­er com­peti­tor to its block­buster Eylea. San­doz’s biosim­i­lar can­di­date afliber­cept proved equiv­a­lent to the brand-name eye drug in a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER